Kazia Therapeutics Limited American Depositary Shares - KZIA STOCK NEWS

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) provided an update on its oncology pipeline, focusing on paxalisib and EVT801. The GBM AGILE study for paxalisib is recruiting nearly 25 sites ahead of schedule in the U.S., with over 650 patients screened to date. The phase II study of paxalisib has seen its final patient complete treatment, while the phase I study of EVT801 has submitted its protocol to French regulators. Kazia anticipates upcoming data releases from ongoing studies in 2021.

Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a collaboration with Weill Cornell Medical College for a Phase II clinical trial examining paxalisib combined with a ketogenic diet for glioblastoma treatment. This study aims to explore the potential of ketogenesis in enhancing paxalisib's effectiveness and reducing side effects like hyperglycemia. Led by Dr. Howard Fine, the trial will consist of two arms, with an initial cohort of 16 patients in each. Recruitment is expected to start by the end of 2021, pending regulatory approvals.

Kazia Therapeutics Limited (NASDAQ: KZIA) has initiated a phase II clinical study of its investigational drug, paxalisib, targeting primary CNS lymphoma at the Dana-Farber Cancer Institute. The study, which has enrolled its first patient, aims to recruit a total of 25 patients over the next two years. Paxalisib is the only PI3K inhibitor capable of penetrating the blood-brain barrier, addressing a significant treatment gap for patients with CNS lymphoma. Kazia is providing support for the trial, including the study drug and financial grant.

Kazia Therapeutics Limited (NASDAQ: KZIA) announced that its CEO, Dr. James Garner, will present virtually at the LD Micro Invitational XI on June 9, 2021, at 5 PM ET. The company is advancing its lead program, paxalisib, in a pivotal study for glioblastoma and expects to begin clinical trials for a new program, EVT801, in 2021. The LD Micro Invitational runs from June 8-10, showcasing around 180 companies. Investors can register for free at the event's website.

Kazia Therapeutics has expanded its pipeline by acquiring EVT801, a small molecule inhibitor targeting VEGFR3, from Evotec for €1m upfront plus potential milestones of €308m and tiered single-digit royalties. EVT801, developed in collaboration with Sanofi, is currently in preclinical development, with a Phase I study expected to launch by the end of CY21. The company increased its valuation to US$247m or US$19.14 per basic ADR, up from US$215m. This expansion also raises Kazia's financing requirement to US$36m from US$7m, reflecting increased R&D spending.

Kazia Therapeutics has entered a worldwide exclusive licensing agreement with Evotec SE for EVT801, a first-in-class oncology drug candidate. Kazia will pay €1 million upfront and up to €308 million in contingent milestones. EVT801, a small-molecule VEGFR3 inhibitor, targets lymphangiogenesis to combat tumor growth and may enhance immuno-oncology therapies. The phase I clinical trial is expected to launch in 2021, focusing on cancers such as renal cell carcinoma and hepatocellular carcinoma. This collaboration aims to expedite EVT801's development.

Kazia (NASDAQ:KZIA) has secured an agreement with Simcere Pharmaceuticals for the Greater China rights to paxalisib. The deal entails an upfront payment of US$11 million, comprising US$7 million in cash and US$4 million in equity. Additionally, the agreement includes up to US$281 million in milestone payments and mid-teen royalties. This strategic move reduces Kazia's expected financing needs from US$14 million to US$7 million and increases the company's valuation to US$215 million, or US$16.60 per basic ADR.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) has announced a licensing agreement with Simcere Pharmaceutical Group to develop and commercialize its investigational drug, paxalisib, in Greater China. Kazia will receive an upfront payment of US$11 million, including US$7 million in cash and US$4 million in equity. The deal allows Kazia to retain rights outside Greater China and continue its GBM AGILE study. The licensing deal could yield up to US$281 million in milestone payments and royalties from commercial sales, directly funding further development of paxalisib.

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB for Cantrixil, a clinical-stage drug candidate for ovarian cancer. Oasmia will provide an upfront payment of US$ 4 million, with additional milestone payments of up to US$ 42 million, plus royalties on sales. The deal follows positive Phase I study results for Cantrixil, which targets chemotherapy-resistant cancer cells. Oasmia plans to initiate a Phase II trial in 2022.